The US FDA accepts MDSAP audits in lieu of routine inspections. Hence, a single MDSAP audit can demonstrate compliance with both ISO 13485:2016 and FDA’s Quality System Regulation (21 CFR Part 820). For manufacturers, this reduces the burden of undergoing separate FDA inspections. However, for US FDA readiness, manufacturers must align their ISO 13485:2016 QMS with 21 CFR Part 820 (QSR) and FDA-specific requirements. This provides continuous assurance to the FDA that the company’s QMS remains effective and aligned with U.S. regulatory expectations. In this blog, we have presented how to tailor MDSAP audit readiness checklist for US market.
MDSAP requirements specific for the US market
1. Quality management system (QMS Alignment)
The U.S. FDA accepts MDSAP audit reports in place of routine inspections. However, the QMS must align with both ISO 13485:2016 and 21 CFR Part 820 (Quality System Regulation). This means procedures must be documented, implemented, and maintained to meet dual compliance. FDA auditors pay particular attention to design controls, CAPA, and complaint handling. Companies should conduct internal audits to verify that their QMS bridges ISO requirements with FDA-specific expectations.
2. Design controls
Design controls are a cornerstone of FDA’s QSR and a critical focus in MDSAP audits. Hence, MDSAP audit readiness checklist for US market should factor in design controls. Firms must establish documented procedures for design planning, input, output, verification, validation, and transfer. Evidence of risk management integration throughout the design lifecycle is expected. Auditors will look for traceability between user needs, design specifications, and final product performance.
3. CAPA (Corrective and Preventive Action)
CAPA is one of the most scrutinized areas during MDSAP audits. FDA expects robust root cause analysis, documented corrective actions, and preventive measures to avoid recurrence. Companies must demonstrate effectiveness checks to prove CAPA actions resolved the issue. Weak CAPA systems are often cited as major nonconformities. Hence, proactive monitoring is essential.
4. Complaint handling
FDA requires manufacturers to maintain complaint files and investigate product issues systematically. MDSAP auditors will verify that complaints are evaluated for reportability. Procedures must ensure timely investigation, documentation, and corrective action where necessary. Complaint handling links directly to CAPA, making it a high-risk area if not managed properly.
5. Purchasing controls and supplier management
FDA emphasizes supplier oversight as part of QSR compliance. Manufacturers must evaluate, select, and monitor suppliers based on their ability to meet specified requirements. MDSAP auditors will expect documented supplier qualification, risk assessment, and ongoing performance monitoring. Supplier audits and scorecards are strong evidence of compliance readiness.
6. Production and process controls
Processes must be validated in cases where results cannot be fully verified by subsequent inspection or testing. FDA expects documented procedures, monitoring, and control of manufacturing processes. Evidence of equipment calibration, maintenance, and operator training is critical. MDSAP auditors will check for consistency between documented processes and actual practices in medical device manufacturing.
7. Document and record controls
FDA requires strict control of documents and records to ensure accuracy, accessibility, and retention. MDSAP auditors will verify that procedures exist for document approval, distribution, and revision. Records must demonstrate compliance with both ISO 13485 and FDA QSR requirements. Electronic systems must meet FDA’s 21 CFR Part 11 requirements for electronic records and signatures.
8. Adverse event reporting
FDA mandates adverse events reporting, which is a critical U.S.-specific requirement under MDSAP. Hence, MDSAP audit readiness checklist for US market should focus on adverse event reporting. Companies must have procedures to identify, evaluate, and report adverse events within required timelines. Auditors will check complaint files and CAPA records for adverse events. Failure to comply with adverse events requirements is a serious regulatory risk and can lead to enforcement actions.
MDSAP audit readiness checklist with US FDA focus
We have prepared an MDSAP audit readiness checklist tailored for the US FDA market.
1. Align QMS with ISO 13485 and 21 CFR Part 820
Verify your Quality Management System covers both ISO 13485:2016 and FDA’s Quality System Regulation. This should be top priority in the MDSAP audit readiness checklist. Ensure procedures are documented, implemented, and consistently followed across all departments. Additionally, conduct internal audits to confirm bridging of ISO clauses with FDA-specific requirements. Maintain evidence that your QMS is effective and continuously monitored.
2. Have design controls in place
Establish documented procedures for design planning, inputs, outputs, verification, validation, and transfer. Integrate risk management throughout the design lifecycle with clear traceability. Moreover, maintain records linking user needs to design specifications and final product performance. Furthermore, control and validate all design changes before implementation.
3. Implement robust CAPA system
MDSAP audit readiness checklist should require robust CAPA system implementation. Implement robust root cause analysis for all nonconformities. Document corrective and preventive actions with clear timelines. Perform effectiveness checks to confirm CAPA actions resolved issues. Trend CAPA data to identify systemic risks and prevent recurrence.
4. Effective complaint handling
Maintain complaint files with systematic investigation procedures. Document corrective actions linked to complaints where necessary. Additionally, integrate complaint handling with CAPA for continuous improvement.
5. Have supplier and purchasing controls in place
MDSAP audit readiness checklist should cover supplier and purchasing controls. Evaluate and qualify suppliers based on their ability to meet requirements. Document supplier risk assessments and ongoing performance monitoring. Moreover, maintain supplier audits and scorecards as compliance evidence. Furthermore, ensure purchasing controls align with FDA’s QSR expectations.
6. Production and process controls
Document procedures for monitoring and controlling manufacturing processes. Maintain calibration, maintenance, and training records for equipment and operators. Ensure actual manufacturing practices match documented procedures.
7. Establish document and record controls
Document and record controls should be prioritised for MDSAP audit readiness checklist. Establish procedures for document approval, distribution, and revision. Ensure records demonstrate compliance with ISO 13485 and FDA QSR. Retain records in line with FDA requirements for accessibility and accuracy. Furthermore, validate electronic systems to meet 21 CFR Part 11 standards.
8. Adverse event reporting system
Implement procedures to identify, evaluate, and report adverse events. Additionally, train staff on adverse event reporting timelines and reporting obligations. Moreover, link complaint files and CAPA records to adverse event triggers for traceability. Furthermore, monitor compliance continuously to avoid further risks.
We have presented how to tailor the MDSAP audit readiness checklist for the US market. Tailoring MDSAP audit readiness for the U.S. FDA requires more than simply following ISO 13485. It demands a proper integration of FDA’s Quality System Regulation (21 CFR Part 820) into every audit preparation step. By focusing on design controls, CAPA effectiveness, complaint handling, supplier oversight, and adverse event reporting, manufacturers can ensure their systems withstand the dual scrutiny of international standards and FDA-specific expectations. The FDA’s acceptance of MDSAP audits in lieu of routine inspections makes this alignment a strategic advantage, thereby reducing regulatory burden while maintaining high compliance credibility. Finally, a U.S.-tailored MDSAP checklist strengthens audit resilience, accelerates market access, and positions manufacturers for long-term success in a highly regulated environment.
Therefore, a well‑structured MDSAP audit readiness checklist for US FDA is more than just a compliance tool. It is a practical roadmap for audit readiness. Each item in the checklist translates to compliance with both MDSAP and US FDA requirements. By using this checklist, medical device manufacturers can systematically confirm readiness, identify gaps, and assign responsibilities before an audit. This checklist‑driven approach gives teams confidence that they are prepared for FDA scrutiny and MDSAP compliance simultaneously. For assistance with MDSAP certification and US FDA compliance, feel free to email at [email protected] or call/Whatsapp on 9996859227.
